Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

21 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Firazyr Articles

US FDA approves Shire’s Firazyr to treat acute attacks of hereditary angioedema

26 August 2011

FDA advisory panel backs approval of Shire’s Firazyr for HAE; Replagal site cleared by EMA

27 June 2011

US FDA advisory panel says no to Novartis gout drug Ilaris; agency backs safety of Shire’s Firazyr

22 June 2011

Shire presents new data for Replagal and VPRIV; gets PUDFA date for Firazyr

22 March 2011

EU Commission OKs InterMune’s Esbriet and self-admin label for Shire’s Firazyr

4 March 2011

Shire gains extended US approval ADHA drug for Intuniv; files response on Firazyr

2 March 2011

Shire says 2nd-qtr 2010 revenues rose 35% and EPS leapt 71%; updates on Firazyr; Movetis’ Resolor cleared in Switzerland

5 August 2010

Showing 1-7 of 7 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
  • Elan makes "transformational" acquisitions and a divestment
  • HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
  • Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
  • Elan makes "transformational" acquisitions and a divestment
  • HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS